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Cellular eIF2B subunit localization: implications 
for the integrated stress response and its control 
by small molecule drugs
ABSTRACT Eukaryotic initiation factor 2 (eIF2) is a G protein critical for translation. It is 
tightly regulated in the integrated stress response (ISR) via phosphorylation of eIF2α and the 
subsequent control of eukaryotic initiation factor 2B (eIF2B), a multisubunit guanine nucleo-
tide exchange factor. Through studying the localization of eIF2B subunits, we identified cyto-
plasmic eIF2B bodies in mammalian cells. We highlight a relationship between body size and 
the eIF2B subunits localizing to them; larger bodies contain all subunits and smaller bodies 
contain predominantly catalytic subunits. eIF2 localizes to eIF2B bodies and shuttles within 
these bodies in a manner that correlates with eIF2B activity. On stress, eIF2α-P localizes pre-
dominately to larger bodies and results in a decreased shuttling of eIF2. Interestingly, drugs 
that inhibit the ISR can rescue eIF2 shuttling in a manner correlating to levels of eIF2α-P. In 
contrast, smaller bodies show increased eIF2 shuttling in response to stress, which is 
accompanied by the localization of eIF2Bδ to these bodies, suggesting the formation of a 
novel trimeric complex of eIF2B. This response is mimicked by ISR-inhibiting drugs, providing 
insight into their potential mechanism of action. This study provides evidence that the 
composition and function of mammalian eIF2B bodies are regulated by the ISR and the drugs 
that control it.
INTRODUCTION
The complex process by which ribosomes are first recruited to 
mRNA and an appropriate start codon for a protein-coding se-
quence is selected, is defined as translation initiation. In eukaryotes, 
the highly conserved heterotrimeric G-protein eukaryotic initiation 
factor 2 (eIF2) is essential for this process. In its active, guanosine 
triphosphate (GTP) bound form, eIF2 binds to an initiator methionyl-
tRNA (Met-tRNAi) molecule to form a ternary complex (TC). The TC 
is loaded onto the small (40S) ribosomal subunit facilitated by the 
binding of other eIFs, to form a 43S preinitiation complex (PIC). The 
PIC is recruited to the 5′-end of a target mRNA molecule and scans 
the mRNA sequence for a start codon (Hinnebusch and Lorsch, 
2012). On start codon recognition, eIF2-GTP is hydrolyzed medi-
ated by the GTPase-activating protein eIF5 (Huang et al., 1997), re-
ducing the affinity of eIF2 for the Met-tRNAi (Erickson and Hannig, 
1996; Algire et al., 2005). This stimulates the release of other eIFs 
allowing the 60S ribosomal subunit to interact with the 40S 
ribosomal subunit. This initiation process generates a full 80S ribo-
some with an appropriately positioned Met-tRNAi at the start codon 
of an mRNA ready to recruit the next amino-acylated tRNA to the 
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subsequent codon in the translation elongation phase (Hinnebusch 
and Lorsch, 2012).
For subsequent rounds of translation initiation to occur, eIF2-GTP 
must be replenished within the cell. eIF2-guanosine diphosphate 
(GDP) is released from the PIC in complex with eIF5, which functions 
as a GDP dissociation inhibitor (GDI) (Jennings and Pavitt, 2010). eIF2 
has a higher affinity for GDP (Erickson and Hannig, 1996), and thus 
the guanine nucleotide exchange factor (GEF), eukaryotic initiation 
factor 2B (eIF2B), is required for recycling of eIF2-GDP to the GTP-
bound form. Recently, eIF2B was revealed as a dual-functioning pro-
tein. In addition to its GEF activity, eIF2B also acts as a GDI displace-
ment factor (GDF) that can release eIF2-GDP from eIF5 (Jennings 
et al., 2013). Although functionally similar to other GEFs of the Ras 
superfamily, eIF2B exhibits a greater level of complexity within its 
quaternary structure, likely due to its dual role as both a GDF and a 
GEF but also its requirement for translation initiation regulation. 
Structurally, eIF2B is composed of five nonidentical subunits, termed 
α through to ε, encoded in human cells by the genes EIF2B1–5, re-
spectively. The γ and ε subunits of eIF2B have been shown to form a 
catalytic subcomplex, whereas the α, β, and δ subunits are required 
for the regulation of eIF2B activity in response to various cellular sig-
nals (Pavitt et al., 1997, 1998). Structural studies have revealed that 
eIF2B exists as a decamer in its native form (Gordiyenko et al., 2014; 
Wortham et al., 2014), and the recently solved crystal structure of 
Schizosaccharomyces pombe and human eIF2B contains this 
decamer arranged with a eIF2B(αβδ)2 hexameric regulatory core, 
bound by two eIF2B(γε) catalytic subcomplexes on opposite sides 
(Kashiwagi et al., 2016; Tsai et al., 2018; Zyryanova et al., 2018).
Regulation of eIF2B activity provides a critical controlled point in 
the translation initiation pathway. The most well-studied mechanism 
of eIF2B regulation forms part of the integrated stress response 
(ISR), which results in the down-regulation of global protein synthe-
sis and the concomitant expression of stress-specific factors such as 
ATF4. More specifically, in response to cellular stress, protein ki-
nases phosphorylate the α subunit of eIF2 on Ser 51. In mammalian 
cells, there are four eIF2α kinases that are activated in response to 
diverse stress stimuli. These kinases are PKR (protein kinase R), PERK 
(protein kinase RNA-like endoplasmic reticulum kinase), GCN2 
(general control nondepressible 2), and HRI (heme-regulated inhibi-
tor) (Wek et al., 2006). Phosphorylation of eIF2α converts it from a 
substrate to a competitive inhibitor of eIF2B (Rowlands et al., 1988; 
Dever et al., 1995) leading to the down-regulation of global protein 
synthesis. Paradoxically, the translation of a subset of ISR-responsive 
mRNAs, which support adaptive stress responses, is up-regulated 
(Young and Wek, 2016). Conditions that promote eIF2α phosphory-
lation and the inhibition of translation also lead to the formation of 
stress granules. These cytoplasmic granules contain stalled mRNAs 
harboring 40S ribosome subunits, various translation initiation fac-
tors, and RNA-binding proteins (Buchan and Parker, 2009).
Phosphorylated eIF2α binds specifically to the regulatory 
eIF2B(αβδ)2 complex that resides in the center of the eIF2B decamer 
(Pavitt et al., 1997; Kashiwagi et al., 2016, 2017), and the α subunit 
of eIF2B in particular is critical for this regulation (Hannig et al., 
1990; Dever et al., 1993; Fabian et al., 1997; Kimball et al., 1998; 
Elsby et al., 2011). Recently, the small molecule, integrated stress 
response inhibitor (ISRIB) was identified in a cell-based screen for 
inhibitors of PERK activity (Sidrauski et al., 2013). ISRIB reverses 
phosphorylated eIF2α-induced translational repression (Sidrauski 
et al., 2013, 2015a; Halliday et al., 2015) through restoration of 
eIF2B activity (Sekine et al., 2015; Sidrauski et al., 2015b). This res-
toration of eIF2B activity occurs through stabilization of eIF2B in its 
decameric form (Sidrauski et al., 2015b). ISRIB binds at the interface 
between eIF2Bδ and eIF2Bβ promoting the dimerization of two 
eIF2B(βδγε) tetramers and promoting decamer formation (Tsai et al., 
2018; Zyryanova et al., 2018). Recently, the FDA- approved drug 
dibenzoylmethane (DBM) was found to have similar properties to 
ISRIB (Halliday et al., 2017) in that it can reverse stress-induced 
translational depression. However, the mechanism of action of this 
drug remains unknown, with evidence to suggest that unlike ISRIB, 
it may act downstream of eIF2B (Halliday et al., 2017).
It has been established in the yeasts Saccharomyces cerevisiae 
and Candida albicans that eIF2B localizes to large cytoplasmic 
eIF2B bodies (Campbell et al., 2005; Campbell and Ashe, 2006; 
Egbe et al., 2015; Moon and Parker, 2018). These bodies represent 
sites where GEF activity occurs and are potentially associated with 
eIF2B regulation (Taylor et al., 2010). Overexpression of eIF2B sub-
units in mammalian cells suggests that eIF2B might form subcom-
plexes that possess different sensitivities to regulation (Liu et al., 
2011; Wortham et al., 2014). The significance of eIF2B localization in 
terms of the control of protein synthesis has not been investigated 
in mammalian cells.
The importance of elucidating the mechanisms of eIF2B function 
in mammalian cells is heightened by the fact that mutations in eIF2B 
lead to the neurological disorder leukoencephalopathy with vanish-
ing white matter (VWM). Mutations most commonly occur in the ε 
subunit of eIF2B; however, causative mutations in all five subunits of 
eIF2B have been identified (Fogli and Boespflug-Tanguy, 2006). 
Although eIF2B is a global regulator of protein synthesis, VWM pri-
marily manifests as a leukodystrophy characterized by immature as-
trocytes and an increased number of oligodendrocyte progenitor 
cells (Dooves et al., 2016). In addition to neurological symptoms, 
some patients also present with ovarioleukodystrophy and in severe 
cases, multiple organs are defective, with the severity of the patient 
symptoms inversely related to age at onset (Bugiani et al., 2010; 
Hamilton et al., 2018). The cellular mechanisms through which muta-
tions cause VWM pathophysiology remain elusive. A number of 
VWM mutations have been shown to affect eIF2B complex formation 
or function; however, some mutations do not impact either of these 
factors yet cause severe disease (Liu et al., 2011; Wortham and 
Proud, 2015). Characterizing eIF2B cellular localization may provide 
a tool to further investigate the mechanisms of VWM pathology.
Here we investigated eIF2B localization in human astrocytic cells 
and show that eIF2B localizes to heterogeneous populations termed 
eIF2B bodies. These bodies appear to differ in size and eIF2B sub-
unit makeup. We show that all eIF2B subunits localize to the larger 
eIF2B bodies, and the shuttling of eIF2 through these bodies ap-
pears to be down-regulated by the induction of cellular stress. Inter-
estingly, the ISR inhibitor, ISRIB, attenuates the effects of stress on 
eIF2 shuttling through these bodies in a manner that correlates to 
levels of phosphorylated eIF2α. In contrast to the larger eIF2B bod-
ies, the shuttling of eIF2 through small eIF2B bodies is increased in 
response to cellular stress. This increase in the shuttling of eIF2 ap-
pears to be accompanied by an increase in the localization of eIF2Bδ 
to the small eIF2B bodies. Suprisingly, translation-enhancing drugs, 
which target the ISR, appear to mimic the effect that stress has on 
eIF2 shuttling and eIF2Bδ localization to small eIF2B bodies. We 
propose these two populations of eIF2B bodies, which are differ-
ently regulated by the ISR, may be important in mediating the cell’s 
response to stress. Larger eIF2B bodies provide a source of eIF2B 
that can be inhibited during stress and promote ISR-specific up-
regulation of stress-responsive genes, whereas small eIF2B bodies 
provide a source of eIF2B that is not inhibited by cellular stress, al-
lowing for low levels of translation to occur so the cell can overcome 
the stress.
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RESULTS
eIF2B localizes to a heterogeneous population of 
cytoplasmic bodies in mammalian glial cells
To study the cellular localization of eIF2B in human glial cells, the ε 
subunit of eIF2B bearing a C-terminal green fluorescent protein 
(GFP) tag was transiently transfected into the astrocytoma cell line, 
U373 (Figure 1A). Under normal cellular growth conditions, we ob-
served that eIF2Bε-GFP localized to cytoplasmic foci, which we have 
termed eIF2B bodies (Figure 1B). Intriguingly, within a population of 
cells, the number and size of these bodies varied quite dramatically. 
We initially characterized the bodies by size; classified them into 
large (≥10 µm2), medium (≥3 µm2 ≤9.99 µm2), and small (≤2.99 µm2); 
FIGURE 1: eIF2Bε localizes to cytoplasmic bodies in U373 cells. (A) eIF2Bε-GFP was expressed in U373 cells, confirmed 
by Western blot analysis. (B) Live cell confocal images of U373 cells expressing eIF2Bε-GFP (i) showing localization to 
only large (L) (≥10 µm2), (ii) only medium (M) (≥3 µm2 ≤9.99 µm2), (iii) only small (S) (≤2.99 µm2), and (iv) a mixture (Mix) of 
L, M, or S eIF2B bodies. (C) (i) The median percentage of cells, in a population of 100 cells, exhibiting eIF2Bε-GFP 
localized to only L, only M, only S, a mix of different-sized eIF2B bodies, or dispersed (n = 3); (ii) within the population of 
cells containing a Mix of eIF2B bodies, the mean number of L, M, and S eIF2B bodies. (D) Confocal images of 
endogenous eIF2B subunits localizing to cytoplasmic bodies. U373 cells were fixed in methanol and subject to ICC with 
(left to right) anti-eIF2Bα, anti-eIF2Bβ, anti-eIF2Bδ, anti-eIF2Bγ, or anti-eIF2Bε primary antibodies and visualized using 
appropriate secondary antibodies conjugated to Alexa Fluor 488.
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and observed populations of cells containing only large (Figure 1Bi), 
only medium (Figure 1Bii), only small (Figure 1Biii), and a mixture 
(Figure 1Biv) of the different-sized bodies. To characterize these dif-
ferent subpopulations, we carried out counts across 100 cells (Figure 
1Ci). A minor population of cells (11%) with entirely dispersed local-
ization was also observed. The counts revealed that cells containing 
a mixture of different-sized bodies were the most frequent. On fur-
ther investigation of these mixed populations, it appeared that on 
average, these cells contained one large body, two medium bodies, 
and >15 small bodies (Figure 1Cii). We have also observed popula-
tions of eIF2B bodies in other cell types, demonstrating that this 
localization is not a specific feature of glial cells (Supplemental 
Figure S1A). To ensure that this localization was not a result of tran-
sient overexpression of eIF2B, immunostaining was carried out for 
endogenous eIF2B subunits. As shown in Figure 1D, localized foci 
of each subunit of eIF2B are clearly visible.
Owing to the size of the eIF2B bodies, we wanted to ensure that 
these bodies were not the result of ubiquitin-directed protein ag-
gregation and therefore aggregsomes of misfolded proteins. While 
ubiquitination can target cells for a number of functions, only the 
presence of poly-ubiquitin targets specific proteins for degradation 
by the proteasome (Kleiger and Mayor, 2014). To test this, immuno-
fluorescence was perfomed on cells using the poly-ubiquitin FK1 
antibody. As shown in Supplemental Figure S1B, eIF2B bodies do 
not colocalize with aggregates of poly-ubiquitin, suggesting they 
are not sites of misfolded proteins.
Another possibility for this localization could be that the GFP tag 
itself may be responsible for the observed aggregation rather than 
the eIF2Bε subunit. To address this, cells expressing a GFP-only con-
trol plasmid were visualized and no localized foci were observed 
(Supplemental Figure S2A). Furthermore, we observed cytoplasmic 
foci with eIF2Bε C-terminally tagged with myc (Supplemental Figure 
S2B). Quantification of cells harboring eIF2Bε-myc revealed a similar 
pattern of distribution to the GFP-tagged subunit (Supplemental 
Figure S2C, i and ii), providing further evidence the eIF2Bε subunit 
is responsible for the observed localization.
Translation initiation factors are known to aggregate to stress 
granules during stress (Kedersha and Anderson, 2002). To confirm 
that these eIF2B bodies are distinct from stress granules, cells were 
exposed to either ER stress using thapsigargin (Tg) or oxidative 
stress using sodium arsenite (SA). The stress granule markers G3BP 
and eIF3b were used to identify stress granules. On exposure to 
both stresses, G3BP and eIF3b aggregated into distinct stress gran-
ules; however, no colocalization of these stress granules with eIF2B 
bodies was observed in these cells, confirming the eIF2B bodies as 
distinct cytoplasmic foci (Supplemental Figure S3, A and B).
Hence, we demonstrate that eIF2B can localize to cytoplasmic 
bodies in human cells. These findings have similarities with our previ-
ous work carried out in yeast cells, where cytoplasmic eIF2B bodies 
were identified (Campbell et al., 2005). However, unlike yeast cells, 
the human eIF2B bodies are more abundant and diverse in size.
eIF2 localizes with eIF2B bodies and can rapidly shuttle 
through these sites
eIF2B is the GEF for eIF2, and a key feature of the yeast eIF2B bod-
ies is the colocalization of eIF2 (Campbell et al., 2005). We next 
investigated if eIF2 localized to eIF2B bodies. To test this, cells 
expressing eIF2Bε-GFP were subjected to immunocytochemistry 
(ICC) with an anti-eIF2α antibody. eIF2α localized to all eIF2B bod-
ies, independent of size (Figure 2A). In yeast, the shuttling of eIF2 
through eIF2B bodies in live cells has been shown to correlate with 
eIF2B GEF activity (Campbell et al., 2005; Singh et al., 2011). To 
assess whether eIF2 in mammalian eIF2B bodies undergoes similar 
dynamics, fluorescence recovery after photobleaching (FRAP) analy-
sis was carried out. Prebleach, bleach, and recovery data were 
collected for each size of eIF2B body (Figure 2B). No recovery of 
eIF2Bε-GFP was observed after FRAP across any of the different 
sizes of eIF2B bodies, suggesting that eIF2B is a relatively stable 
component of the eIF2B bodies. In contrast, recovery of eIF2α-GFP 
was observed for all categories of eIF2B bodies. Figure 2C shows 
the percentage of recovery relative to fluorescence in prebleach 
images for eIF2α-GFP and eIF2Bε-GFP within i) large, ii) medium, 
and iii) small bodies over a 12-s time period.
These data show that, as in S. cerevisiae (Campbell et al., 2005; 
Taylor et al., 2010) in human astrocytoma cells, eIF2 can rapidly tran-
sit through the eIF2B body, whereas eIF2B is a stable component. In 
addition, this shuttling of eIF2 was observed in all of the different-
sized eIF2B bodies.
eIF2B subunits display unique localization patterns to 
different-sized eIF2B bodies
eIF2B exists as a decamer in its native form. Having shown that 
eIF2Bε localizes to cytoplasmic bodies and that eIF2 can shuttle 
through these foci, we next investigated whether other eIF2B sub-
units colocalized with these bodies. U373 cells expressing eIF2Bε-
GFP were subjected to ICC with antibodies against the eIF2Bα, β, δ, 
and γ subunits. Representative images are shown in the panels of 
Figure 3A. The four eIF2B subunits show discrete patterns of colocal-
ization to the eIF2Bε cytoplasmic bodies in cells containing small, 
medium, large, and a mixture of different-sized bodies. Intriguingly, 
100% colocalization was not observed for all the subunits. For each 
subunit, we characterized the percentage of cells showing colocal-
ized bodies, and these counts revealed that each eIF2B subunit had 
a unique pattern of colocalization with the eIF2Bε bodies (Figure 
3Bi). Within these populations of cells, we next determined whether 
the percentage of colocalization observed correlated with the size of 
the eIF2B body (Figure 3Bii). Remarkably, a correlation was observed 
between the composition and size of the eIF2B body. For example, 
for the large eIF2B bodies, all of the subunits colocalized with a 
median percentage colocalization of greater than 85%. For the small 
population of eIF2B bodies, eIF2Bγ showed the highest level of co-
localization (65%), with the regulatory subunits showing medians of 
less than 15% for eIF2Bδ and 0% for eIF2Bα and eIF2Bβ (Figure 3Bii). 
Like the large eIF2B bodies, all subunits colocalized with the medium 
eIF2B bodies; however, a greater variation among subunits was ob-
served. eIF2Bγ again had the highest level of colocalization (86%); 
this was followed by eIF2Bδ (74%), eIF2Bβ (51%), and eIF2Bα (36%).
Here we have demonstrated that mammalian eIF2B bodies differ 
in size, and that this classification system broadly correlates to the 
subunits present. The large and medium bodies contain all subunits 
of eIF2B whereas, intriguingly, the small eIF2B bodies seem to rep-
resent a different subcomplex of eIF2B that predominately consists 
of eIF2Bγ and ε, the catalytic subunits of eIF2B. While these eIF2B 
subcomplexes have been shown to be formed in vitro (Li et al., 
2004), this is one of the first pieces of evidence that suggest that 
these subcomplexes, lacking regulatory subunits of eIF2B, are 
formed in vivo.
Phosphorylated eIF2α localizes to large and medium eIF2B 
bodies during cellular stress and movement of eIF2 through 
these bodies is impaired
In response to various stress conditions, eIF2α is phosphorylated at 
serine 51 by an eIF2α kinase, inhibiting eIF2B activity and stimulat-
ing the ISR. This regulation is specifically carried out by the regulatory 
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subunits of eIF2B, and in particular eIF2Bα, which recognizes and 
binds the phosphorylated eIF2α (Kimball et al., 1998). As the large 
and medium eIF2B bodies (greater than 3 µm2) contained all sub-
units, we hypothesized that only these bodies would respond to 
stress and so initially focused our analysis on these eIF2B bodies. SA 
and Tg were used to induce eIF2α phosphorylation, and the levels 
of eIF2α phosphorylation induced by each of these stresses were 
determined using Western blot analysis (Figure 4A). Two concentra-
tions of SA treatment were used, resulting in various levels of eIF2α 
phosphorylation. The Tg treatment also induced eIF2α phosphory-
lation to a lesser degree than both SA treatments.
To determine whether phosphorylated eIF2α localized to the 
large and medium eIF2B bodies, ICC using an antibody to phos-
phorylated eIF2α was performed. Phosphorylated eIF2α localized to 
these eIF2B bodies; however, cytoplasmic foci distinct from the 
eIF2B bodies were also observed (Figure 4B). Phosphorylated eIF2α 
is known to aggregate in stress granule (SG) on the stress conditions 
used here (Kedersha et al., 1999), and thus the observed foci of 
FIGURE 2: eIF2α associates with eIF2B bodies and can shuttle into these sites. (A) Confocal images of U373 cells 
transfected with eIF2Bε-GFP, fixed in methanol, and subject to ICC with a primary anti-eIF2α antibody, and visualized 
using an appropriate Alexa Fluor 568–conjugated secondary antibody. (B) FRAP analysis was carried out on (i) eIF2α-
GFP localized to eIF2B bodies in U373 cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B body and on 
(ii) eIF2Bε-GFP in U373 cells transfected with eIF2Bε-GFP. Panels show representative prebleach (pb), bleach (b), and 
recovery (r) images from FRAP experiments. (C) Normalized FRAP curves for eIF2α-GFP and eIF2Bε-GFP recovery to 
(i) large, (ii) medium, and (iii) small eIF2B bodies. For large, medium, and small bodies, FRAP analysis was performed on 
10 bodies (n = 3). The percentage recovery is presented as mean ± SEM.
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phosphorylated eIF2α distinct from eIF2B bodies are likely to be 
SGs. The percentage colocalization of phosphorylated eIF2α in both 
large and medium bodies was determined and is shown in Figure 
4C. In untreated cells, the majority of eIF2B bodies did not show 
colocalization with phosphorylated eIF2α localized; however, follow-
ing induction of stress, phosphorylated eIF2α was observed to colo-
calize with eIF2B bodies (Figure 4C). Both concentrations of SA 
induced a significant increase in the percentage colocalization of 
phosphorylated eIF2α, whereas a smaller increase in the percentage 
colocalization was observed for Tg-treated cells (Figure 4C). This is 
likely due to the lower level of phosphorylated eIF2α induced by the 
Tg treatment (Figure 4A).
The observed increase in the level of phosphorylated eIF2α 
associated with the large and medium eIF2B bodies after stress 
FIGURE 3: eIF2B (α–γ) subunits colocalize with eIF2B bodies. (A) Confocal images of U373 cells transfected with 
eIF2Bε-GFP, fixed in methanol, and subject to ICC with primary (i) anti-eIF2Bα, (ii) anti-eIF2Bβ, (iii) anti-eIF2Bδ, and 
(iv) anti-eIF2Bγ antibodies. All antibodies were visualized using appropriate secondary antibodies conjugated to Alexa 
Fluor 568. (B) (i) For eIF2Bα, eIF2Bβ, eIF2Bδ, or eIF2Bγ subunits, the percentage of cells that showed colocalization to 
eIF2Bε-GFP bodies (n = 3 counts of 50 cells). Within the population of cells that showed colocalization, (ii) the median 
percentage of colocalization for eIF2Bα, β, δ or γ subunits with large, medium and small eIF2Bε-GFP bodies (n = 3 
counts of 50 cells).
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FIGURE 4: In the presence of Tg- or SA-induced cellular stress, phosphorylated eIF2α localizes to large and medium 
eIF2B bodies decreasing movement of eIF2 through these bodies. (A) Western blot analysis of the level of eIF2α and 
eIF2α p[S51] expression in U373 cells treated with 500 µM SA, 125 µM SA, or 1 µM Tg to induce cellular stress. Levels of 
phosphorylated eIF2α were normalized to levels of total eIF2α and presented as mean ± SD (n = 3). (B) U373 cells were 
transfected with eIF2Bε-GFP and treated with 500 µM SA, 125 µM SA, or 1 µM Tg. Cells were fixed in methanol and 
subject to ICC with a primary anti-eIF2α p[S51] antibody. The anti-eIF2α p[S51] antibody was visualized using an 
appropriate Alexa Fluor 568–conjugated secondary antibody and imaged using confocal microscopy. (C) The median 
percentage of anti-eIF2α p[S51] colocalized to large and medium eIF2Bε-GFP bodies (≥3 µm2) was determined in a 
population of 50 cells (n = 3). (D) FRAP analysis was carried out on eIF2α-GFP localized to large and medium eIF2B 
bodies in U373 cells transfected with eIF2α-GFP in addition to eIF2Bε-RFP to mark the eIF2B bodies. Cells were treated 
with 1 µM Tg, 125 µM SA, or 500 µM SA to induce cellular stress. FRAP analysis was performed on 10 bodies (n = 3). 
The mean ± SEM percentage of eIF2α-GFP recovery was determined from normalized FRAP recovery curves. (E) FRAP 
analysis was carried out on eIF2α-GFP localized to large and medium eIF2B bodies in U373 cells transfected with 
eIF2α-GFP wt or eIF2α-GFP S51A mutant, in addition to eIF2Bε-RFP to mark the eIF2B bodies. Cells were treated with 
500 µM SA to induce cellular stress. FRAP analysis was performed on 10 bodies (n = 2). The mean ± SEM percentage of 
eIF2α-GFP recovery was determined from normalized FRAP recovery curves. p Values were derived from a Kruskal-
Wallis test, followed by a Conover-Inman analysis, *p ≤ 0.05.
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(Figure 4C) is consistent with the higher affinity of phosphorylated 
eIF2α for eIF2B. The tighter binding sequesters eIF2B leading to 
decreased eIF2B GEF activity (Ramaiah et al., 1994; Pavitt et al., 
1998). Based on our studies in yeast (Campbell et al., 2005), the pres-
ence of increased phosphorylated eIF2α in eIF2B bodies should re-
duce the level of eIF2 shuttling. To assess this, eIF2α-GFP shuttling 
was monitored in the large and medium bodies after treatment with 
either Tg or SA. In response to all stress treatments, these eIF2B bod-
ies showed a significant decreased recovery of eIF2 (Figure 4D and 
Supplemental Figure S4A). The greatest decrease in recovery was 
observed for the higher concentration of SA (500 µM), followed by 
the lower concentration of SA (125 µM) and then Tg. This decrease 
in eIF2 recovery directly correlates with the levels of phosphorylated 
eIF2α observed in Figure 4A and a reduction in total protein synthe-
sis as observed by puromycin incorporation assays (Figure 5A). To 
confirm that this reduced shuttling of eIF2 was in response to the 
increased levels of phosphorylated eIF2α, FRAP activity was ana-
lyzed in the presence of an eIF2α mutant where Ser51 is replaced by 
Ala. This mutant cannot be phosphorylated, as confirmed by West-
ern blot (Supplemental Figure S4C) and therefore cannot inhibit 
eIF2B GEF activity during cellular stress. FRAP analysis following 
stress treatment with the higher concentration of SA (500 µM) re-
vealed that the eIF2α S51A mutant could still shuttle through the 
eIF2B body, while the wild-type (WT) eIF2α exhibited severe reduc-
tion in shuttling (Figure 4E and Supplemental Figure S4B). These 
data suggest that the ability of eIF2 to recover within eIF2B bodies is 
specifically influenced by eIF2α phosphorylation-dependent eIF2B 
regulation.
ISRIB reverses the effects that the ISR has on eIF2 shuttling 
in large and medium eIF2B bodies dependent on levels of 
phosphorylated eIF2α
ISRIB has been identified as a small molecule that renders cells in-
sensitive to the inhibitory effects of eIF2α phosphorylation (Sidrauski 
et al., 2013, 2015a; Halliday et al., 2015) through stabilization of 
decameric eIF2B (Sidrauski et al., 2015b; Tsai et al., 2018; Zyryanova 
et al., 2018). We therefore investigated whether ISRIB could attenu-
ate the inhibitory effect of eIF2α phosphorylation on protein synthe-
sis and eIF2 shuttling through the large and medium eIF2B bodies. 
ISRIB treatment alone did not affect levels of phosphorylated eIF2α 
(Figure 5B) and had little effect on the rate of protein synthesis or 
eIF2 recovery to eIF2B bodies (Figure 5, A and C). Puromycin incor-
poration assays confirmed that ISRIB could overcome the inhibitory 
effects of Tg on protein synthesis but not at the higher concentra-
tion of SA (500 µM) (Figure 5A). These data are consistent with 
previous studies that highlighted that ISRIB can restore protein 
synthesis when the ratio of nonphosphorylated eIF2 exceeds that of 
phosphorylated eIF2 (Sidrauski et al., 2015a).
FRAP analysis was carried out on cells treated with Tg or SA in the 
presence of ISRIB. A carrier-only control (dimethyl sulfoxide–treated 
cells) did not show any significant difference in the recovery of eIF2α 
(Supplemental Figure S5). For Tg-treated cells, ISRIB was found to 
significantly increase the recovery of eIF2 to untreated levels (Figure 
5C and Supplemental Figure S5Ai). A similar trend was observed for 
the lower concentration of SA (125 µM) (Figure 5D and Supplemental 
Figure S5Aii), whereas ISRIB could not rescue the recovery of eIF2 at 
the higher SA concentration (500 µM) (Figure 5E and Supplemental 
Figure S5Aiii). Thus, our favored interpretation for these observations 
is that under high levels of phosphorylated eIF2α, and therefore a 
higher ratio of phosphorylated to unphosphorylated protein, the 
level of ISRIB used is incapable of reversing the inhibitory effect of 
eIF2α phosphorylation on the recovery of eIF2.
During stress small eIF2B bodies increase in number and 
show an increased recovery of eIF2 and a redistribution of 
eIF2Bδ
We have shown that in response to cellular stress, phosphorylated 
eIF2α localizes to large and medium eIF2B bodies and this corre-
lates with a decrease in the rate of eIF2 shuttling, suggesting that 
these bodies can be regulated via the ISR. We hypothesize that this 
regulation is due to the presence of regulatory subunits within these 
large and medium bodies. Interestingly, we have also shown that 
eIF2 can shuttle through all eIF2B bodies including small bodies 
(Figure 2Ciii). As these small eIF2B bodies predominantly contained 
eIF2Bγ and eIF2Bε (Figure 3Bii), we hypothesized that the recovery 
of eIF2 in small bodies would not be affected during stress. Surpris-
ingly, both Tg and the lower concentration of SA (125 µM) signifi-
cantly increased the recovery of eIF2 in these small bodies, whereas 
in contrast, a decrease in the percentage recovery of eIF2 was ob-
served for the higher concentration of SA (500 µM) (Figure 6A and 
Supplemental Figure S5B, i–iii). As the decrease in shuttling of eIF2 
in the large and medium eIF2B bodies correlated with the presence 
of phosphorylated eIF2α, we hypothesized that this lack of recovery 
of eIF2 in small bodies at the higher concentration of SA (500 µM) 
may be due to an increase in localization of phosphorylated eIF2α. 
In agreement with this when colocalization of phosphorylated eIF2α 
with small bodies was analyzed, an increase in localization was 
observed under all stress treatments with the greatest increase 
observed for the higher concentration of SA (Figure 6B).
Interestingly, increased GEF activity of eIF2B has been linked to 
subunit composition, specifically the presence of regulatory sub-
units (Fabian et al., 1997; Williams et al., 2001; Dev et al., 2010; Liu 
et al., 2011). To address whether the stress treatments had any im-
pact on the distribution of regulatory subunits within the small eIF2B 
bodies, which could possibly explain this increased recovery of eIF2, 
ICC analysis was carried out. Interestingly, the percentage of eIF2Bδ 
colocalizing to the small eIF2B bodies increased by over 40% for all 
stresses (Figure 6C).
Having shown under stress the subunit composition of small 
eIF2B bodies is altered, we were intrigued to determine whether the 
number of these bodies also changed. We carried out counts across 
50 cells and observed no change to the average number of large 
and medium bodies under stress; however, the number of small 
bodies increased for all stress treatments (Figure 6D). These data 
suggest small eIF2B bodies show a different response to stress 
when compared with the large and medium bodies.
ISRIB treatment mimics the effect of stress on small eIF2B 
bodies
We next investigated whether ISRIB had any impact on small body 
activity and composition. Rather surprisingly, we identified that IS-
RIB treatment significantly increased the degree to which eIF2 
shuttles through the small eIF2B bodies (Figure 7A and Supple-
mental Figure S5Biv). The level of increase of eIF2 shutting seen 
on ISRIB treatment is similar to the increase observed for Tg and 
SA (125 µM) treatments. Furthermore, an increased number of 
small bodies and also localization of eIF2Bδ to the small bodies 
was observed (Figure 7B), a similar trend to all stress conditions 
(Figure 6, C and D).
ISRIB has been shown to restore eIF2B activity through stabiliza-
tion of eIF2B in its decameric form (Tsai et al., 2018; Zyryanova et al., 
2018). However, our data suggest that ISRIB may also promote the 
localization of eIF2Bδ to small eIF2B bodies to which catalytic sub-
units localize. To confirm that this movement of eIF2Bδ was a spe-
cific response to ISRIB exposure, we made use of an ISRIB-resistant 
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FIGURE 5: ISRIB reverses the effects that the ISR has on eIF2 shuttling in large and medium eIF2B bodies in a manner 
dependent on levels of phosphorylated eIF2α. (A) (i) Puromycin incorporation assays were carried out on U373 cells 
treated with 200 nM ISRIB or 1 µM Tg and 500 µM SA alone or in combination with 200 nM ISRIB. (ii) Levels of 
puromycin where normalized to β-actin and are presented as mean ± SD for each treatment normalized to control cells 
(n = 3). (B) Western blot analysis of the level of eIF2α and eIF2α p[S51] expression in U373 cells treated with 200 nM 
ISRIB for 1 h. FRAP analysis was carried out on eIF2α-GFP localized to large and medium eIF2B bodies in U373 cells 
transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B bodies. Cells were treated with 200 nM ISRIB alone or in 
combination with (C) 1 µM Tg, (D) 125 µM SA, or (E) 500 µM SA. FRAP analysis was performed on 10 bodies (n = 3) the 
mean ± SEM percentage of eIF2α-GFP recovery was determined from normalized FRAP recovery curves; control and 
stress treatment data from Figure 4D are reshown for relevance. p Values derived from a Kruskal-Wallis test, followed by 
a Conover-Inman analysis, *p ≤ 0.05.
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FIGURE 6: On stress, the number of small eIF2B bodies within the cell increase and these bodies show an increased 
recovery of eIF2 and a redistribution of eIF2Bδ. (A) FRAP analysis was carried out on eIF2α-GFP localized to small eIF2B 
bodies in U373 cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B bodies. Cells were treated with 
1 µM Tg, 125 µM SA, or 500 µM SA. FRAP analysis was performed on 10 bodies (n = 3) and the mean ± SEM percentage 
of eIF2α-GFP recovery was determined from normalized FRAP recovery curves. (B) U373 cells were transfected with 
eIF2Bε-GFP and treated with 1 µM Tg, 125 µM SA, or 500 µM SA. Cells were fixed in methanol and subject to ICC with 
a primary anti-eIF2α p[S51] antibody. The anti-eIF2α p[S51] antibody was visualized using an appropriate Alexa Fluor 
568–conjugated secondary antibody, and the median percentage of anti-eIF2α p[S51] colocalized to small eIF2Bε-GFP 
bodies was determined in a population of 50 cells (n = 3). (C) U373 cells were transfected with eIF2Bε-GFP and treated 
with 1 µM Tg, 125 µM SA, or 500 µM SA. Cells were fixed in methanol and subject to ICC with a primary anti-eIF2Bδ 
antibody and visualized using an appropriate secondary antibody conjugated to Alexa Fluor 568. Within a population of 
50 cells, the median percentage of colocalization between anti-eIF2Bδ and small eIF2B bodies was determined (n = 3). 
(D) U373 cells were transfected with eIF2Bε-GFP, and treated with 1 µM Tg, 125 µM SA, or 500 µM SA. Counts were 
performed to determine the median number of large and medium (L and M) or small (S) eIF2B bodies within a 
population of 50 cells (n = 3). p Values derived from a Kruskal-Wallis test, followed by a Conover-Inman analysis, 
*p ≤ 0.05.
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FIGURE 7: ISRIB treatment mimics the effect of stress on small eIF2B bodies. (A) FRAP analysis was carried out on 
eIF2α-GFP localized to small eIF2B bodies in U373 cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B 
bodies. Cells were treated with 200 nM ISRIB and FRAP analysis was performed on 10 bodies (n = 3) The percentage of 
eIF2 that recovered is presented as mean ± SEM. (B) U373 cells were transfected with eIF2Bε-GFP and treated with 
200 nM ISRIB. (i) The median number of large and medium (L and M) or small (S) eIF2Bε-GFP bodies was determined 
within a population of 50 cells (n = 3). (ii) Cells were fixed in methanol and subject to ICC with a primary anti-eIF2Bδ 
antibody and visualized using an appropriate secondary antibody conjugated to Alexa Fluor 568. Within a population of 
50 cells, the median percentage of colocalization between anti-eIF2Bδ and large and medium (L and M) or small 
(S) eIF2Bε-GFP bodies was determined (n = 3). (C) (i) CHO cells containing eIF2Bδ (WT) or eIF2Bδ (L180F) were subject 
to dot blot analysis for anti-eIF2Bδ. (ii) The cells were transfected with eIF2Bε-RFP and treated with 200 nM ISRIB. Cells 
were fixed in methanol and subject to ICC with a primary anti-eIF2Bδ antibody and visualized using an appropriate 
secondary antibody conjugated to Alexa Fluor 568. Within a population of 25 cells, the median percentage of 
colocalization between anti-eIF2Bδ and large and medium (L and M) or small (S) eIF2Bε-RFP bodies was determined 
(n = 3). (iii) Representative images showing the localization of eIF2Bδ to small bodies in eIF2Bδ (WT) and eIF2Bδ (L180F) 
CHO cells in the presence or absence of ISRIB treatment. p Values derived from a Kruskal-Wallis test, followed by a 
Conover-Inman analysis, *p ≤ 0.05.
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mutation in eIF2Bδ (L180F) (Sekine et al., 2015). CHO cells contain-
ing wild type (WT) eIF2Bδ or mutant eIF2Bδ (L180F) were trans-
fected with eIF2Bε-red fluorescent protein (RFP), and a similar pat-
tern of eIF2B body localization was observed for both sets of cells 
(Figure 7Ciii). To ensure that the eIF2Bδ mutant did not affect anti-
body recognition, dot blot analysis was carried out. Analysis of ex-
tracts prepared from both the WT and the mutants cells showed 
eIF2Bδ was recognized to similar levels in both sets of cells (Figure 
7Ci). On ISRIB treatment, as for U373 cells, an increase in eIF2Bδ 
localization to small bodies was observed for the WT eIF2Bδ. Inter-
estingly, in the mutant cells, no increase in distribution of mutant 
eIF2Bδ (L180F) to small bodies was observed (Figure 7C, ii and iii). 
These data suggest that the redistribution of eIF2Bδ to small bodies 
in response to ISRIB is a direct effect of ISRIB interaction with eIF2Bδ.
DBM treatment has an effect similar to that of ISRIB on 
small eIF2B body dynamics
We next determined whether this effect of ISRIB on small bodies 
was unique to ISRIB or whether other drugs, which block the activa-
tion of the ISR, also result in similar effects. To test this, we exposed 
cells to the drug DBM. DBM is a naturally occurring structural ana-
logue of curcumin, with widely reported anti-cancer properties, and 
was recently identified in a drug screen to identify compounds that 
decrease the unfolded protein response (UPR) activity in cells and 
allow a restoration of protein synthesis (Halliday et al., 2017).
FRAP analysis on DBM-treated cells showed that, like ISRIB, 
DBM did not affect the recovery of eIF2 in large or medium bodies 
but increased the degree to which eIF2 shuttles through the 
small eIF2B bodies (Figure 8A and Supplemental Figure S5Bv). 
FIGURE 8: DBM shows an effect on small eIF2B bodies similar to that of ISRIB. (A) FRAP analysis was carried out on 
eIF2α-GFP localized to small eIF2B bodies in U373 cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B 
bodies. Cells were treated with 20 µM DBM. FRAP analysis was performed on 10 bodies (n = 3), and the percentage of 
eIF2 that recovered is presented as mean ± SEM. (B) U373 cells were fixed in methanol and subject to ICC with a 
primary anti-eIF2Bδ antibody and visualized using an appropriate secondary antibody conjugated to Alexa Fluor 568. 
Within a population of 50 cells, the median percentage of colocalization between anti-eIF2Bδ and large and medium 
(L and M) or small (S) eIF2Bε-GFP bodies (n = 3) is shown. p Values derived from a Kruskal-Wallis test, followed by a 
Conover-Inman analysis, *p ≤ 0.05.
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Intriguingly, a similar increase in eIF2Bδ localization was observed in 
the small bodies on DBM treatment (Figure 8B). These data suggest 
that DBM may have an effect on small bodies similar to that 
observed for ISRIB.
DISCUSSION
Previous work in the yeasts S. cerevisiae and C. albicans has shown 
that eIF2B localizes to cytoplasmic foci, termed eIF2B bodies 
(Campbell et al., 2005; Egbe et al., 2015), and eIF2 was shown to 
shuttle through these bodies. Three different strategies to decrease 
the guanine nucleotide exchange function of eIF2B all inhibited 
eIF2 shuttling into the foci, showing that in yeast, the measurement 
of eIF2 shuttling through the eIF2B body correlates precisely with 
eIF2B GEF activity (Campbell et al., 2005). Here we have extended 
these studies to look at the functional localization of eIF2B in mam-
malian cells, which has not previously been evaluated.
We show that eIF2B bodies exist in mammalian cells and eIF2 
can shuttle through these bodies. Unlike in yeast where cells exhib-
ited a single eIF2B body, mammalian cells exhibit populations of 
different-sized bodies. This difference in eIF2B body distribution 
from yeast to mammalian cells is likely due to differences in organ-
ism complexity. Structural analysis of eIF2B has shown that eIF2B 
forms a heterodecamer in its native form (Gordiyenko et al., 2014; 
Wortham et al., 2014; Kashiwagi et al., 2016, 2017), but can also 
form eIF2B subcomplexes that contain varying degrees of the 
individual eIF2B subunits on overexpression. Biochemical analysis 
showed that these eIF2B subcomplexes differ in GEF activity in vitro 
(Liu et al., 2011; Wortham et al., 2014). The eIF2B subunit localiza-
tion data presented here suggest that the eIF2B subcomplexes, 
which have been shown to form in vitro, also exist in mammalian 
cells under normal growth conditions. In this study, we have catego-
rized the different-sized eIF2B bodies based on their eIF2B subunit 
composition, with large and medium bodies (greater than 3 µm2) 
containing all subunits and smaller bodies (less than 3 µm2) contain-
ing predominantly catalytic subunits, eIF2Bγ and eIF2Bε.
Activation of the ISR by diverse cellular stresses results in the 
phosphorylation of eIF2α at serine 51. Phosphorylated eIF2 is a 
competitive inhibitor of eIF2B (Rowlands et al., 1988; Dever et al., 
1995) causing the down-regulation of translation initiation. The 
eIF2B regulatory subunits (α, β, and δ) are essential for mediating 
the control of eIF2B activity under stress (Pavitt et al., 1997; 
Krishnamoorthy et al., 2001), and eIF2B complexes containing the 
regulatory subunits are known to display a higher affinity for 
eIF2 when present in its phosphorylated form (Pavitt et al., 1998; 
Kashiwagi et al., 2017). We postulate that having populations of 
eIF2B subcomplexes, where regulatory subunits are either present 
or absent, may be an important mechanism in the cellular response 
to stress. FRAP analysis of eIF2 shuttling through the eIF2B bodies 
has revealed that during stress, large and medium eIF2B bodies (to 
which the eIF2B regulatory subunits predominately localize) show 
attenuated eIF2 shuttling in response to ER and oxidative stress, 
induced by Tg and SA, respectively. Analysis of the cellular localiza-
tion of phosphorylated eIF2 in these cells demonstrated that 
phosphorylated eIF2 localized predominately to these bodies. Ad-
ditionally, puromycin incorporation assays show a decrease in total 
protein synthesis under the same stress conditions, demonstrating a 
correlation among global protein synthesis, the shuttling of eIF2 
through, and localization of phosphorylated eIF2α to these eIF2B 
bodies. In addition, the decrease in shuttling of eIF2 through these 
bodies during stress is directly related to the phosphorylation of 
eIF2. eIF2 harboring an S51A mutation that prevents phosphoryla-
tion does not show the same decrease in shuttling observed for WT 
eIF2 during stress. This evidence supports our previous conclusions 
in yeast where we observed that the rate of recovery of eIF2 in FRAP 
analysis is relative to the amount of GEF activity in the eIF2B bodies 
(Campbell et al., 2005; Taylor et al., 2010).
ISRIB has recently been identified as an inhibitor of the ISR, re-
versing the effects of eIF2α phosphorylation (Sidrauski et al., 2013, 
2015a). ISRIB has been shown to stabilize eIF2B in its decameric 
form, increasing eIF2B GEF activity and restoring translation in 
stressed cells (Tsai et al., 2018; Zyryanova et al., 2018). As the shut-
tling of eIF2 in large and medium bodies (which contain all subunits) 
decreases in a manner correlating with an increased presence of 
phosphorylated eIF2α, we hypothesized that if ISRIB can restore 
eIF2B activity, it would rescue eIF2 shuttling within these foci. We 
found this hypothesis to be true for cells treated with Tg and a low 
concentration of SA (125 µM). However, ISRIB was unable to rescue 
eIF2 shuttling through these bodies in cells treated with a higher SA 
concentration (500 µM). This higher concentration of SA induced 
greater levels of eIF2α phosphorylation; therefore, our results 
suggest that ISRIB can restore eIF2 shuttling in a manner that is de-
pendent on the precise levels of eIF2α phosphorylation. This is in 
agreement with previous studies where ISRIB has been shown to 
restore eIF2B activity when levels of nonphosphorylated eIF2 are 
greater than levels of phosphorylated eIF2 (Sidrauski et al. 2015b).
In addition to observing large and medium eIF2B bodies (con-
taining all subunits of eIF2B), we also observed small bodies (less 
than 3 µm2), which predominately contained eIF2Bγ and eIF2Bε. In 
vitro GEF assays, in both yeast and mammalian cells, show that 
eIF2Bγε heterodimers exhibit GEF activity that is unregulatable by 
phosphorylated eIF2α (Pavitt et al., 1998; Li et al., 2004). We showed 
that eIF2 localized to these small bodies and was mobile within 
them. We therefore hypothesized that shuttling of eIF2 would not 
be down-regulated by stress due to the absence of regulatory sub-
units in these bodies. Intriguingly, we found eIF2 shuttling through 
small bodies was in fact significantly increased by cellular stress 
induced by both Tg and a low concentration of SA (125 µM). There-
fore, eIF2 shuttling through these small bodies is not down-regu-
lated by stress and is in fact enhanced. Biochemical assays in yeast 
have demonstrated that increasing the expression of regulatory 
eIF2B subunits can enhance GEF activity (Fabian et al., 1997; 
Williams et al., 2001; Dev et al., 2010; Liu et al., 2011). Interestingly, 
we have observed an increase in the localization of eIF2Bδ to eIF2B 
small bodies under stress treatment, which may be responsible for 
the observed increase in eIF2 shuttling. This is suggestive of the 
formation of a currently unidentified subcomplex containing eIF2Bδ, 
γ, and ε, which has a role in the cellular ISR. This complex may not 
have been previously identified in research that analyzed eIF2B 
subcomplexes, as such studies did not observe cells under stress. 
Future studies are required to directly test this hypothesis.
In contrast, when cells were treated with a higher concentration 
of SA (500 µM), shuttling of eIF2 through small eIF2B bodies was 
reduced. This higher SA treatment induced a greater increase in the 
level of eIF2α phosphorylation when compared with the other two 
stress treatments. Phosphorylated eIF2α is a competitive inhibitor of 
eIF2B that exhibits greater affinity for eIF2B than unphosphorylated 
eIF2α (Rowlands et al., 1988). In these cells, we saw a greater induc-
tion of phosphorylated eIF2α localizing to these small bodies, and 
thus our favored explanation for this result is that in the presence of 
high levels of phosphorylated eIF2α, all eIF2B complexes become 
inhibited independent of subunit makeup.
In recent years, low levels of cellular stress have been shown to 
be protective. Preconditioning cells through the induction of low 
levels of phosphorylated eIF2α appears to prime cells to overcome 
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stress (Lu et al., 2004; Lewerenz and Maher, 2009). Our data suggest 
that small eIF2B bodies have greater GEF activity under stress, and 
perhaps these small bodies may be important in providing a source 
of eIF2B activity that is not inhibited by stress, thus allowing cells to 
respond and recover from stress. Recent work in S. cerevisiae has 
observed that induction of stress results in an increase in eIF2B 
bodies (Moon and Parker, 2018). Interestingly, we did not see an 
increase in the number of large eIF2B bodies; rather, we observed 
an increase in the number of small bodies under stress. This further 
suggests that in mammalian cells, these smaller bodies are impor-
tant for the cell to respond to stress. Further investigations into the 
effects that stress has on eIF2B composition may provide a greater 
insight into how cells respond to stress.
The change in small eIF2B body subunit dynamics in response to 
stress also appears to be driven by ISRIB treatment, where we 
observed similar increases in the number of small bodies, eIF2 
shuttling, and redistribution of eIF2Bδ to these bodies. Mutational 
analysis has confirmed that this redistribution of eIF2Bδ is a direct 
effect of ISRIB. These results appear somewhat self-contradictory, as 
cellular stress promotes eIF2α phosphorylation, inhibiting eIF2B 
GEF activity, whereas ISRIB opposes these effects and promotes 
eIF2B GEF activity. Recent data have shown that ISRIB can stabilize 
decameric eIF2B and increase the GEF activity in a dose-dependent 
manner (Wong et al., 2018). In addition to these effects, our data 
suggest that during stress, ISRIB promotes the formation of small 
eIF2B bodies containing eIF2Bδ, which appears to have increased 
GEF activity that is not down-regulated on low levels of stress. It has 
previously been suggested that in addition to its role in stabilizing 
the eIF2B decamer, ISRIB may also enhance the basal activity of 
eIF2B by providing a source of eIF2B that is not inhibited by phos-
phorylated eIF2α, allowing sufficient levels of ternary complex to 
sustain protein translation and overcome stress (Sidrauski et al., 
2015b). We therefore hypothesize that the effect of ISRIB on the 
small eIF2B bodies may be responsible for providing a source of 
eIF2B that is active during stress.
Recently, the drug DBM was identified to have similar properties 
to ISRIB in decreasing UPR activity in cells and allowing a restoration 
of protein synthesis (Halliday et al., 2017). However, unlike ISRIB, 
DBM was shown not to stabilize the eIF2B decameric complex, and 
its mechanism of action remains largely unknown. DBM-treated cells 
also showed an increased localization of eIF2Bδ to small bodies, 
correlating with an increase in eIF2 shuttling through these bodies, 
and these data suggest that eIF2Bδ, γ, and ε subcomplexes may be 
involved in DBM’s mechanism of action, again providing a source of 
eIF2B that can remain active under stress conditions.
eIF2B consolidates into large cytoplasmic bodies in both yeasts 
and mammalian cells. The situation in mammalian cells is more 
intricate, as eIF2B bodies of various sizes exist with various subunit 
compositions. The large and medium eIF2B bodies harbor regula-
tory subunits and likely represent sites of GEF activity vulnerable to 
stress-induced repression. The small eIF2B bodies are mainly com-
posed of catalytic eIF2B subunits and appear to be differentially 
regulated by the ISR, likely providing a level of eIF2B GEF activity 
during stress that allows cells to survive and respond. The presence 
of these diverse bodies in different abundances may allow different 
cell types to harbor unique stress responses and perhaps contribute 
to the tissue specificity of VWM, a key area of future research.
MATERIALS AND METHODS
Cell culture
U373 astrocytoma cells were cultured in MEM, supplemented with 
10% (vol/vol) fetal bovine serum (FBS), 1% (wt/vol) nonessential 
amino acids, 1% (wt/vol) sodium pyruvate, 1% (wt/vol) glutamine, 
and 1% (wt/vol) penicillin/streptomycin, all purchased from Life 
Technologies. MG-63 cells were cultured in RPMI supplemented 
with 10% (vol/vol) FBS and 1% (wt/vol) penicillin/streptomycin. 
HEK293 and HepG2 cells were cultured in DMEM supplemented 
with 10% FBS (vol/vol) and 1% (wt/vol) penicillin/streptomycin. 
CHO-C30 cells and CHO-C30 cells harboring the L180F mutation 
within the eIF2B4 gene (Sekine et al., 2015) were a kind gift from D. 
Ron (Cambridge Institute for Medical Research). Cells were cultured 
in Nutrient Mixture F12 Ham (Sigma) supplemented with 10% 
fetal calf serum (vol/vol) (FetalClone II; Thermo) and 1% (wt/vol) 
penicillin/streptomycin, (Life Technologies). All cells were main-
tained at 37°C under 5% CO2 and were routinely tested for contami-
nation with MycoAlert Mycoplasma Detection Kit purchased from 
Lonza (Slough, UK).
Plasmids
pCMV6-AC-GFP plasmid vectors encoding EIF2B5 and EIF2S1 were 
purchased from OriGene (Rockville, MD). The coding open reading 
frame (ORF) of EIF2B5 from the pCMV6-AC-GFP vector was cloned 
into a pCMV6-AC-RFP vector (OriGene). The construct was verified 
by sequencing. Site-directed mutagenesis was performed on the 
EIF2S1 plasmid to generate an S51A mutation using a QuikChange 
II Site-Directed Mutagenesis Kit (Agilent, Stockport, UK) in accor-
dance with manufacturer’s instructions. The construct was verified 
by sequencing. pHM2Bε was a kind gift from N. Wortham (Univer-
sity of Southampton, Southhampton, UK).
Transient transfections
One day prior to transfection, CHO cells were seeded at a density 
of 1 × 105 cells, and all other cells were seeded at a density of 8 × 
104 cells in a six-well plate or fluorodish. Transfections were per-
formed by chemical transfection with 1 mg/ml polyethylenimine 
(PEI; Sigma-Aldrich, Dorset, UK). Plasmid DNA (1–3 µg) was diluted 
in 100 µl of serum and antibiotic-free cell culture medium. Diluted 
DNA was mixed with PEI and incubated at room temperature (RT) 
for 10 min. The volume of PEI used was based on a 3:1 ratio of PEI 
(µg):plasmid DNA (µg). Antibiotic-free cell culture media (600 µl) 
was added to the transfection mix, and the total volume was added 
to the cells. Cells were incubated at 37°C for 23 h, with an additional 
2 ml of antibiotic-free media added at the 2.5-h point. Cell culture 
media was changed to complete media and cells were incubated at 
37°C for 24–48 h prior to imaging.
Protein analysis
Cells were washed with phosphate-buffered saline (PBS) (Sigma- 
Aldrich) and lysed in CelLytic M (Sigma-Aldrich) containing protease 
inhibitor cocktail (Sigma-Aldrich), as per manufacturer’s instructions. 
Cell lysates were subject to a bicinchoninic acid (BCA) protein assay 
to determine the protein concentration. Bovine serum albumin 
(BSA; Sigma-Aldrich) was diluted in CelLytic M to make appropriate 
standards to generate a standard curve. Ten microliters of each 
sample/standard was incubated with 200 µl of BCA reagent 
(0.4% [wt/vol] copper sulfate in BCA) for 30 min and the absorbance 
at 570 nm determined. Protein samples were concentrated, where 
appropriate, using Viva spin 2 columns (Fisher Scientific) in accor-
dance with the manufacturer’s instructions. For dot blot analysis, 
1 µl of protein samples was applied to a nitrocellulose membrane 
and allowed to air dry. Membranes were blocked in Tris-buffered 
saline supplemented with 0.1% (vol/vol) Tween 20 (TBST) and 5% 
(wt/vol) nonfat milk (Premier Foods, London, UK) for 1 h. Primary 
antibodies were diluted in block solution and incubated with 
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membranes overnight. Membranes were then washed in TBST and 
incubated for 1 h with appropriate LiCor (Cambridge, UK) second-
ary antibodies diluted 1:10,000 in 5% (wt/vol) nonfat milk in TBST. 
Dot blots were visualized on a LiCor Odyssey Scanner with Image 
Studio Lite software. For Western blot analysis, protein samples 
were diluted in 4 × SDS–PAGE sample buffer (Expedeon, Swavesey, 
UK) and incubated at 95°C for 4 min. Total protein (60 µg) was re-
solved on a 10% polyacrylamide gel and transferred onto nitrocel-
lulose membrane. Membranes were blocked in 5% (wt/vol) nonfat 
milk or BSA in TBST and probed with primary antibodies diluted in 
TBST supplemented with 5% (wt/vol) nonfat milk. The following an-
tibodies were used: eIF2Bε (1:500, ARP61329_P050; Aviva Systems 
Biology, San Diego, CA), eIF2Bγ (1:500, sc-137248; Santa Cruz Bio-
technology, Dallas, TX), eIF2α (1:100, sc-11386; Santa Cruz Biotech-
nology), and phospho-eIF2α (ser51) (1:1000, 44728G, Invitrogen, 
Fisher Scientific); and β-actin (1:1000, ab8224; Abcam, Cambridge, 
UK). Membranes were then washed with TBST, probed with LiCor 
secondary antibodies (1:10,000, goat anti-rabbit IRDye 680RD P/N 
925-68071 and 1:10,000 goat anti-mouse IRDye 800CW P/N 925-
32210; LiCor), and visualized on a LiCor Odyssey Scanner with 
Image Studio Lite software.
ICC
Cells were grown on coverslips in six-well plates and transfected as 
described above. Cells were fixed in ice-cold methanol (Fisher Sci-
entific) at –20°C for 15 min. Following fixation, cells were washed 
with PBS supplemented with 0.5% (vol/vol) Tween 20 (PBST), three 
times for 3 min, and then blocked in PBS supplemented with 1% 
(wt/vol) BSA. Cells were then washed with PBST, three times for 
3 min, and probed with primary antibodies diluted in PBS supple-
mented with 1% (wt/vol) BSA overnight at 4°C. The following 
antibodies were used: eIF2Bα (1:25, 18010-1-AP; Proteintech, Man-
chester, UK), eIF2Bβ (1:25, 11034-1-AP; Proteintech), eIF2Bδ (1:50, 
sc-271332; Santa Cruz Biotechnology), eIF2Bγ (1:50, sc-137248; 
Santa Cruz Biotechnology), eIF2Bε (1:500, ARP61329_P050; Aviva 
Systems Biology), eIF2α (1:20, FL-315 sc-11386; Santa Cruz Bio-
technology), and phospho-eIF2α (ser51) (1:100, ab32157; Abcam), 
eIF2Bγ (1:100, 11296-2-AP; Proteintech), myc (1:100, ab18185; 
Abcam), G3BP (1:100, ab56574; Abcam), eIF3b (1:100, ab40799; 
Abcam), poly-ubiquitinylated conjugates, and FK1 (1:100, BML-
PW8805; Enzo). Following primary antibody incubation, cells were 
washed with PBST, four times for 3 min, probed with an appropriate 
Alexa Fluor–conjugated secondary antibody (Thermo Fisher Scien-
tific), and diluted in PBS supplemented with 1% (wt/vol) BSA for 
1 h at RT. Cells were then washed with PBST four times for 3 min 
and mounted using VECTASHIELD HardSet Antifade Mounting 
Medium with 4′,6-diamidino-2-phenylindole (Vector Laboratories, 
Burlingame, CA). Cells were viewed on a Zeiss LSM 510 or Zeiss 
LSM 800 confocal microscope.
Confocal Imaging and FRAP analysis
Imaging was performed using either a Zeiss LSM 510 or a Zeiss LSM 
800 confocal microscope. The LSM 510 confocal was used with 
Zeiss 2009 software, a 40 X plan-apochromat oil objective, and an 
argon laser with a maximum output of 25 mW at 55% laser transmis-
sion. The LSM 800 confocal was used with Zen Blue software, a 40X 
plan-apochromat oil objective, and a diode laser with a maximum 
output of 10 mW at 0.2% laser transmission. For FRAP analysis, the 
LSM 510 confocal microscope was used. Bleaching was carried out 
with 23 iterations and 100% laser power (488-nm argon laser). An 
image was captured before bleaching, and then after bleaching, 12 
images were captured for 589.82 ms, with a 600-ms interval. After 
generation of prebleach, bleach, and recovery images, the images 
from each experiment were analyzed in accordance to the method-
ology by Campbell and Ashe (2007). FRAP curves were fitted using 
a one-phase association equation. The percentage of eIF2 recovery 
was determined as the mobile phase of the recovery curve – the 
percentage of unbleached proteins that recovered.
Cell treatments
To induce cellular stress, cells were treated with 1 µM Tg for 1 h, or 
125 µM SA for 30 min, or 500 µM SA for 1 h, with or without the 
addition of 200 nM ISRIB (Sigma-Aldrich). For DBM treatment, cells 
were incubated with 20 µM DBM for 1 h.
Puromycin incorporation assays
The 6.7 × 105 cells were seeded in T75 flasks. One day later, culture 
media were changed to fresh media and cells were either untreated 
or treated with 1 µM Tg or 500 µM SA with or without the addition 
of 200 nM ISRIB, as described above. For puromycin labeling, 91 
µM puromycin (Thermo Fisher) and 208 µM emetine (Sigma-Aldrich) 
were added during the last 5 min before harvest. Cells were washed 
twice in ice-cold PBS containing 355 µM cycloheximide (Calbio-
chem), immunoblot analysis was carried out as described earlier 
using a primary antibody for puromycinylated protein (1:500, clone 
12D10, MABE343; Merck), and a primary antibody for β-actin 
(1:2000, ab8227; Abcam) was used as a loading control.
Measurements and statistical analysis
To determine the statistical significance of the difference among 
groups of data, the data were first subject to a Shapiro-Wilk test for 
normality. Data were considered parametric when p < 0.05. All data 
were found to be nonparametric. For the comparison of three or 
more groups of data, a Kruskal-Wallis test was performed followed 
by a Conover-Inman post-hoc test. Differences in data were consid-
ered significant when p < 0.05.
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